Ru Liu-Bryan

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Rheumatoid Arthritis

Top Venues

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Arthritis & rheumatology (Hoboken, N.J.)

Arthritis research & therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2024)
Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 (5) (2024)
Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 (5) (2024)
Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 (5) (2024)
Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 (5) (2024)
Paulo Gil Alabarse, Patricia Oliveira, Huaping Qin, Tiffany Yan, Marie Migaud, Robert Terkeltaub, Ru Liu-Bryan
The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 73 (5) (2024)
Paulo Gil Alabarse, Liang-Yu Chen, Patricia Oliveira, Huaping Qin, Ru Liu-Bryan
Targeting CD38 to suppress osteoarthritis development and associated pain after joint injury in mice. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Khaled A Elsaid, Tony Raymond Merriman, Leigh-Ana Rossitto, Ru Liu-Bryan, Jacob Karsh, Amanda Phipps-Green, Gregory D Jay, Sandy Elsayed, Marwa Qadri, Marin Miner, Murray Cadzow, Talia J Dambruoso, Tannin Schmidt, Nicola Dalbeth, Ashika Chhana, Jennifer Höglund, Majid Ghassemian, Anaamika Campeau, Nancy Maltez, Niclas G Karlsson, David J Gonzalez, Robert Terkeltaub
Amplification of inflammation by lubricin deficiency implicated in incident, erosive gout independent of hyperuricemia. Arthritis & rheumatology (Hoboken, N.J.) (2022)
Charles McWherter, Yun-Jung Choi, Ramon L Serrano, Sushil K Mahata, Robert Terkeltaub, Ru Liu-Bryan
Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. Arthritis research & therapy 20 (1) (2018)